Health

Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy

by Curtis Jones
written by Curtis Jones 0 comments

Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.

You may also like

Can a vibrating belt help protect bones and muscle health? : NPR

USAID ‘whistleblower’ assesses U.S. response to Ebola : NPR

When U.S. foreign aid changed, AIDS workers in Africa felt it : NPR

Texas has detected a flesh-eating parasite in livestock after 60 years

One of the world’s most isolated islands is being transformed : NPR

Weakened public health powers could hamper states’ outbreak responses : NPR

Leave a Comment

Save my name, email, and website in this browser for the next time I comment.

AdSense Space

UFC Freedom 250: White House event challenged by federal lawsuit

Recent Articles

LIV Golf could run out of money before final 2026 events, exec reportedly says
J.T. Poston’s uber-popular driver model notches its first PGA Tour win
Used Toyota hybrids are selling for more than new — here’s why

Featured

UFC Freedom 250: White House event challenged by federal lawsuit
LIV Golf could run out of money before final 2026 events, exec reportedly says
J.T. Poston’s uber-popular driver model notches its first PGA Tour win

@2025 – All Right Reserved. Designed and Developed by  Kaniz Fatema